Literature DB >> 26365670

Increased Body Mass Index Is Associated with Congestive Heart Failure and Mortality in Adult Fontan Patients.

Sara C Martinez1, Mirnela Byku1, Eric L Novak1, Ari M Cedars1, Pirooz Eghtesady2, Philip A Ludbrook1, Joseph J Billadello1.   

Abstract

OBJECTIVE: Obesity affects adults with congenital heart disease (CHD). The effect of an increased body mass index (BMI) with respect to morbidity and mortality has not been evaluated in adults with complex CHD. Our objective was to evaluate the effects of increased BMI on heart failure and mortality in univentricular patients who had undergone Fontan palliation.
METHODS: A query of Fontan patients' first appointments at the Washington University Center for Adults with CHD between 2007 and 2014 yielded 79 patients. BMI status as normal (<25 kg/m(2) ), overweight (≥25, <30 kg/m(2) ), and obese (≥30 kg/m(2) ) was established at the patient's first appointment. We analyzed demographics, diuretic requirements, New York Heart Association (NYHA) class, and laboratory values using Student's two-sample t-test and Fisher's exact test. Mortality was assessed via survival curves, and hazard ratios were compiled with proportional hazard modeling.
RESULTS: The recent average BMI was significantly greater in patients with NYHA classes II-IV (29.3 ± 9 kg/m(2) ) compared with asymptomatic patients (24.8 ± 5.1 kg/m(2) , P = .006). Additionally, the average BMI of patients with a high diuretic requirement (≥40 mg/day IV furosemide equivalent) was obese, at 32.15 ± 9.1 kg/m(2) , compared with 25.91 ± 7.3 kg/m(2) for those on no or lower doses of diuretics (P = .009). Eighteen of the 79 patients met an endpoint of death, hospice placement, or cardiac transplant by the study conclusion. Kaplan-Meier analysis from time of first appointment until recent follow-up revealed a significant association between time to combined endpoint and BMI class. Cox proportional hazard modeling with age adjustment yielded a hazard ratio of 3.2 (95% CI 1.096-9.379) for obesity upon first presentation to an adult CHD clinic.
CONCLUSIONS: In patients with univentricular hearts and Fontan palliation, obesity is associated with symptomatic heart failure and mortality.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Congestive Heart Failure; Diuretic Requirement; Fontan; Mortality; Obesity

Mesh:

Substances:

Year:  2015        PMID: 26365670     DOI: 10.1111/chd.12296

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  5 in total

1.  Sizing Up Fontan Failure: Association with Increasing Weight in Adulthood.

Authors:  Ryan D Byrne; Angela J Weingarten; Daniel E Clark; Steven J Healan; Tadarro L Richardson; Shi Huang; Jonathan N Menachem; Benjamin P Frischhertz
Journal:  Pediatr Cardiol       Date:  2021-05-04       Impact factor: 1.655

Review 2.  Metabolic syndrome and coronary artery disease in adults with congenital heart disease.

Authors:  Koichiro Niwa
Journal:  Cardiovasc Diagn Ther       Date:  2021-04

3.  Non-invasive biomarkers of Fontan-associated liver disease.

Authors:  Juliet Emamaullee; Sara Khan; Carly Weaver; Cameron Goldbeck; George Yanni; Rohit Kohli; Yuri Genyk; Shengmei Zhou; Nick Shillingford; Patrick M Sullivan; Cheryl Takao; Jon Detterich; Paul F Kantor; John D Cleveland; Cynthia Herrington; S Ram Kumar; Vaughn Starnes; Sarah Badran; Neil D Patel
Journal:  JHEP Rep       Date:  2021-09-14

Review 4.  Nutritional Management of Patients with Fontan Circulation: A Potential for Improved Outcomes from Birth to Adulthood.

Authors:  Letizia Baldini; Katia Librandi; Chiara D'Eusebio; Antonella Lezo
Journal:  Nutrients       Date:  2022-09-29       Impact factor: 6.706

5.  Body Composition in Young Adults Living With a Fontan Circulation: The Myopenic Profile.

Authors:  Derek Tran; Paolo D'Ambrosio; Charlotte E Verrall; Chantal Attard; Julie Briody; Mario D'Souza; Maria Fiatarone Singh; Julian Ayer; Yves d'Udekem; Stephen Twigg; Glen M Davis; David S Celermajer; Rachael Cordina
Journal:  J Am Heart Assoc       Date:  2020-04-15       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.